(The Hill) — The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results